Message: file_get_contents(https://...@gmail.com&api_key=61f08fa0b96a73de8c900d749fcb997acc09): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
MS Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam UMC location VUmc, Amsterdam, The Netherlands.
Published: November 2024
AI Article Synopsis
* Ongoing randomized controlled trials are exploring different approaches to dosing ocrelizumab, including higher doses, personalized B-cell dosing, and potential treatment discontinuation.
* The proposed roadmap aims to use trial outcomes to improve understanding and effectiveness of anti-CD20 therapies, addressing existing knowledge gaps in MS treatment.
Article Abstract
B-cell depleting therapies are frequently used as high efficacy treatments for multiple sclerosis (MS). We will elaborate on current data and future perspectives of one of the most studied anti-CD20 therapies concerning personalization. Currently, multiple randomized controlled trails are recruiting patients, with three different treatment strategies concerning the dose or the dosing interval of ocrelizumab. These strategies involve higher dosing, B-cell tailored dosing and discontinuation of ocrelizumab. We propose a roadmap (Figure 1), that will incorporate results of current trials to address the current knowledge gaps in pursuit of a more efficient use of anti-CD20 therapies in MS.
